B
BINV
vs
O
OMX Stockholm 30
Over the past 12 months, BINV has underperformed OMX Stockholm 30, delivering a return of -15% compared to the OMX Stockholm 30's +31% growth.
Stocks Performance
BINV vs OMX Stockholm 30
Performance Gap
BINV vs OMX Stockholm 30
Performance By Year
BINV vs OMX Stockholm 30
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
BioInvent International AB
Glance View
BioInvent International AB engages in the research and development of novel and immuno-modulatory antibodies for the treatment of cancer. The company is headquartered in Lund, Skane and currently employs 84 full-time employees. The company went IPO on 2001-06-12. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The firm has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
